Ken Griffin Galecto, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Galecto, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 100 shares of GLTO stock, worth $732. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 30,600
99.67%
Holding current value
$732
Previous $23,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding GLTO
# of Institutions
21Shares Held
1.52MCall Options Held
100Put Options Held
100-
Jim Simons Renaissance Technologies LLC | New York, Ny579KShares$4.24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA221KShares$1.62 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA214KShares$1.57 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA168KShares$1.23 Million0.0% of portfolio
-
State Street Corp Boston, MA44.9KShares$328,7110.0% of portfolio
About Galecto, Inc.
- Ticker GLTO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,395,700
- Market Cap $186M
- Description
- Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...